Amur Minerals Corporation Statement regarding possible offer (4226B)

TIDMAMC

RNS Number : 4226B

Amur Minerals Corporation

02 June 2023

2 June 2023

Amur Minerals Corporation

("Amur" or "the Company")

Statement regarding possible offer

The Board of Amur Minerals Corporation notes the announcement yesterday afternoon by Ascent Resources plc ("Ascent") setting out the terms of a non-binding indicative proposal regarding a possible share offer for the entire issued and to be issued share capital of Amur by Ascent.

Since Q4 2022, and in advance of the completion of the sale of its Kun-Manie Nickel Copper project in the Russian Federation (the "Sale"), Amur has been conducting various high level evaluations and assessments of international private and public resource companies and projects. However, until the Sale had completed and the dividend payment process been announced, the Board has been restricted in its ability to advance discussions with potentially interested parties which included Ascent. The terms of the proposed transaction announced by Ascent were new to the Board and accordingly, it will consider these with regard to this opportunity.

Given the indicative nature of the proposed offer, shareholders are advised to take no action at this stage. There can be no certainty that an offer will be made for Amur, or the terms on which any such offer will be made.

Further announcements will be made as appropriate.

Enquiries:

 
       Company            Nomad and Broker        Public Relations 
  Amur Minerals Corp.    S.P. Angel Corporate         BlytheRay 
                             Finance LLP 
   Robin Young CEO        Richard Morrison           Megan Ray 
                              Adam Cowl              Tim Blythe 
                           +44 (0) 20 3470 
  +7 (4212) 75 56 15             0470           +44 (0) 20 7138 3204

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

OFDNKDBPCBKDQAK

(END) Dow Jones Newswires

June 02, 2023 02:00 ET (06:00 GMT)

Crism Therapeutics (AQSE:AMC.GB)
Historical Stock Chart
From Oct 2024 to Nov 2024